These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24169327)

  • 21. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
    Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
    JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The association of HDL cholesterol concentration with the -629C>A CETP promoter polymorphism is not fully explained by its relationship with plasma cholesteryl ester transfer.
    Dullaart RP; Borggreve SE; Hillege HL; Dallinga-Thie GM
    Scand J Clin Lab Invest; 2008; 68(2):99-105. PubMed ID: 17852818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
    J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CETP (cholesteryl ester transfer protein) promoter -1337 C>T polymorphism protects against coronary atherosclerosis in Japanese patients with heterozygous familial hypercholesterolaemia.
    Takata M; Inazu A; Katsuda S; Miwa K; Kawashiri MA; Nohara A; Higashikata T; Kobayashi J; Mabuchi H; Yamagishi M
    Clin Sci (Lond); 2006 Nov; 111(5):325-31. PubMed ID: 16822236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
    Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
    N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation).
    Nicholls SJ; Tuzcu EM; Brennan DM; Tardif JC; Nissen SE
    Circulation; 2008 Dec; 118(24):2506-14. PubMed ID: 19029466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS).
    Klerkx AH; de Grooth GJ; Zwinderman AH; Jukema JW; Kuivenhoven JA; Kastelein JJ
    Eur J Clin Invest; 2004 Jan; 34(1):21-8. PubMed ID: 14984434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TaqIB and severity of coronary artery disease in the Turkish population: a pilot study.
    Kaman D; İlhan N; İlhan N; Akbulut M
    Bosn J Basic Med Sci; 2015 Feb; 15(1):9-13. PubMed ID: 25725138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
    Arsenault BJ; Barter P; DeMicco DA; Bao W; Preston GM; LaRosa JC; Grundy SM; Deedwania P; Greten H; Wenger NK; Shepherd J; Waters DD; Kastelein JJ;
    J Am Coll Cardiol; 2011 Jan; 57(1):63-9. PubMed ID: 21185503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
    Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Circulation; 2013 Nov; 128(22):2395-403. PubMed ID: 24043299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of torcetrapib on the progression of coronary atherosclerosis.
    Nissen SE; Tardif JC; Nicholls SJ; Revkin JH; Shear CL; Duggan WT; Ruzyllo W; Bachinsky WB; Lasala GP; Tuzcu EM;
    N Engl J Med; 2007 Mar; 356(13):1304-16. PubMed ID: 17387129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of cholesteryl ester transfer protein -629C->A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides.
    Borggreve SE; Hillege HL; Wolffenbuttel BH; de Jong PE; Bakker SJ; van der Steege G; van Tol A; Dullaart RP;
    J Clin Endocrinol Metab; 2005 Jul; 90(7):4198-204. PubMed ID: 15840744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy.
    Atherosclerosis; ; . PubMed ID: 22265126
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.